Published Feb 5, 2018 |
101 Pages |
Pub ID: KLI15596715
The Market and Potential for CRISPR/Cas9 Gene Editing
CRISPR/Cas9 is a revolutionary approach that enables rapid, economical model generation through precise genome editing. From better understanding of disease, to improved drug discovery, to gene-edited animals and food is not an exaggeration to say that every day, new studies continue to leverage the potential of CRISPR to generate novel strategies for modeling diseases and assessing therapeutic intervention. The tool is used in nature by bacteria to adapt to their environment.
Kalorama has studied this market and provides the most authoritative and current review of what is happening with these technologies and what revenues can be expected. This report consolidates the information and trends and provides reliable market estimates for CRISPR technology to 2023. As part of the report's coverage, it provides the following:
- Market Size and Forecast for CRISPR/Cas9 Gene Editing, 2017-2023
- The Market for CRISPR/Cas9 by Region (N. Amer. EU, ROW), 2017-2023 Analysis of Growth Trend by Region
- Market by Application (Cancer Research, Non-Cancer Disease Research, Cancer Diagnostics, Infection Diagnostics, Plant, Food, Biofuel, Drug Discovery, Drug Development, Other)
- Growth Trend, U.S.
- Growth Trend, Outside U.S.
- Market by End User (Hospitals, University, Medical Research Institute, Government), 2017
- Market by End User (Hospitals, University, Medical Research Institute, Government), 2023
- Recent Technology and Market Developments and Medical Studies
- Partnerships Involving CRISPR Gene Editing
Companies in the Market and Partnerships in Gene Editing
In 2018, more than 30 players participate in this market, from large multinational corporations to small, niche life sciences companies. Key players include Agilent, MilliporeSigma, GE Healthcare Dharmcon, GeneScript, Horizon Discovery Group, OriGene, ThermoFisher Scientific, Transposagen, and ToolGen. These companies develop and commercialize various products and services for each of the major gene editing technologies.
The nature of CRISPR’s complex technology requires partnerships between the developers of the technology and the healthcare concerns with distribution strength and a broader product base. These developments are outlined in the report.
Recent Lawsuit and Industry Risk Analysis
Currently, one of the more significant factors in commercializing CRISPR-Cas9 as a viable therapeutic tool is the current legal battles surrounding the technology. The issue started when both the University of California, Berkeley (UCB) and the Broad Institute of MIT (the Broad) both filed patents related to this technology. While there's been some resolution, the report provides an analysis of developments.
Recent CRISPR Market Development
• The most important funding source that fuels a market for research instrumentation is funding from the National Institutes of Health. The following table details grants for CRISPR-based projects, which in 2015 represented 267 million and in 2017 expanded to over 1 billion. Outside the U.S., there is additional research dollars.
• CRISPR-Cas9-based technologies have strongly increased genome engineering efficiencies in bacteria. This has enabled more rapid metabolic engineering of both the model host Escherichia coli and non-model organisms like Clostridia, Bacilli, Streptomycetes and cyanobacteria, opening new possibilities to use these organisms as improved cell factories. The discovery of novel Cas9-like systems from diverse microbial environments will extend the repertoire of applications and broaden the range of organisms in which it can be used to create novel production hosts.
• In December 2017, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies' previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology. CTX001 represents the first gene-based treatment that Vertex exclusively licensed from CRISPR Therapeutics as part of the collaboration.
• GE Healthcare Dharmacon offers an arrayed synthetic form of CRISPR/Cas9 that allows many different assays (e.g., enzymatic, endpoint, secreted factors) to be performed without resorting to antibiotic selection, long time points, or cell splitting. The system designs at least four different guide RNAs per gene, according to the company, so that if the same effect is seen using all four of the guide RNAs for the same gene, then the results are more likely to be biologically relevant.
• January 2017, the FDA proposed draft guidance suggesting modifications intentionally introduced into animal genomes should be regulated in a manner comparable to new drugs, meaning developers would have to show efficacy, animal and human safety, and safety for the environment.
• In late April 2017, researchers from the Broad Institute of MIT and Harvard, other institutes and departments at MIT (Massachusetts Institute of Technology) and Harvard, Howard Hughes Medical Institute, and the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health published an article in Science entitled “Nucleic acid detection with CRISPR-Cas13a/C2c2.” In this article, they describe a CRISPR-based diagnostic (CRISPR-Dx) which they called Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK). This platform combines the Cas13a enzyme (which targets RNA) with isothermal amplification. They authors used this platform to detect the Zika and Dengue virus, pathogenic bacteria, cell-free tumor DNA, and other genetic targets. The lead author for this paper is Feng Zhang, Ph.D. (Broad Institute), one of the pioneers in CRISPR research